Catalyst
Slingshot members are tracking this event:
FDA Accepted SBLA Filing Of Soliris (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 08, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Refractory Generalized Myasthenia Gravis, Sbla, Soliris, Eculizumab
